The estimated Net Worth of Dawn Svoronos is at least $3.41 Millón dollars as of 24 August 2023. Ms. Svoronos owns over 25,000 units of Global Blood Therapeutics stock worth over $1,712,250 and over the last 8 years she sold GBT stock worth over $1,120,912. In addition, she makes $571,995 as Independent Director at Global Blood Therapeutics.
Dawn has made over 14 trades of the Global Blood Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 25,000 units of GBT stock worth $967,500 on 24 August 2023.
The largest trade she's ever made was buying 50,000 units of Global Blood Therapeutics stock on 14 August 2017 worth over $141,000. On average, Dawn trades about 4,252 units every 59 days since 2016. As of 24 August 2023 she still owns at least 25,000 units of Global Blood Therapeutics stock.
You can see the complete history of Ms. Svoronos stock trades at the bottom of the page.
Dawn A. Svoronos serves as Independent Director of the Company. Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry, including extensive commercial work with the multinational pharmaceutical company Merck & Co. Inc., where she held roles of increasing seniority over nearly 25 years of service. Prior to her retirement from Merck in 2011, Ms. Svoronos most recently served as President of Merck in Europe/Canada from 2009 to 2011, President of Merck in Canada from 2006 to 2009 and Vice-President of Merck for Asia Pacific from 2005 to 2006. Ms. Svoronos currently serves on the boards of directors of the following public companies: PTC Therapeutics, Inc., Xenon Pharmaceuticals, Inc. and Theratechnologies Inc. Previously, Ms. Svoronos served on the board of directors of Medivation Inc., from 2013 until its acquisition in 2016, and on the board of directors of Endocyte, Inc., from May 2018 until its acquisition in December 2018. Ms. Svoronos holds a B.A. from Carleton University in Ottawa, Canada. Ms. Svoronos’ qualifications to serve on our Board of Directors include her extensive experience in the global commercialization of pharmaceutical products, including her substantial international commercial experience as well as her leadership experience and her service on the boards of directors of other public companies.
As the Independent Director of Global Blood Therapeutics, the total compensation of Dawn Svoronos at Global Blood Therapeutics is $571,995. There are 20 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
Dawn Svoronos is 66, she's been the Independent Director of Global Blood Therapeutics since 2018. There are 2 older and 19 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Dawn's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... y Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: